New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
04:55 EDTALDR, ALDR, ALDR, ALDR, ALDR, ALDR, CNDO, CNDO, CNDO, CNDO, CNDO, CNDO, ISIS, ISIS, ISIS, ISIS, ISIS, ISIS, PTCT, PTCT, PTCT, PTCT, PTCT, PTCT, OPXA, OPXA, OPXA, OPXA, OPXA, OPXA, SRPT, SRPT, SRPT, SRPT, SRPT, SRPT, XNPT, XNPT, XNPT, XNPT, XNPT, XNPT, SNY, SNY, SNY, SNY, SNY, SNY, BIIB, BIIB, BIIB, BIIB, BIIB, BIIB, SYN, SYN, SYN, SYN, SYN, SYN, CYTK, CYTK, CYTK, CYTK, CYTK, CYTKAmerican Academy of Neurology to hold annual meeting
66th Annual Meeting of the AAN is being held in Philadelphia on April 26-May 3.
News For CYTK;SYN;BIIB;SNY;XNPT;SRPT;OPXA;PTCT;ISIS;CNDO;ALDR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
March 19, 2015
07:35 EDTCNDOCoronado announces formation of Mustang Therapeutics
Subscribe for More Information
07:12 EDTBIIBBiogen price target raised to $500 from $400 at Credit Suisse
Subscribe for More Information
07:10 EDTCNDOCoronado announces licensing agreement with NeuPharma for EGFR inhibitors
Coronado Biosciences announced the execution of an exclusive license agreement with NeuPharma to develop and commercialize novel irreversible, 3rd Generation EGFR inhibitors on a worldwide basis outside of certain Asian countries. The program is currently in pre-clinical development. Under the terms of the agreement, Coronado will pay NeuPharma an up-front licensing fee as well as make development and sales-based milestone payments and will pay a tiered single digit royalty on net sales. Lindsay Rosenwald, Coronado chairman and CEO stated, "NeuPharma has a portfolio of these inhibitors, the most advanced of which could reach the clinic in the first half of 2016."
07:09 EDTSNYSanofi reports top-line results for Lyxumia for cardiovascular safety
Sanofi announced top-line results of the Phase IIIb ELIXA cardiovascular outcomes study, which compared lixisenatide to placebo in a high-risk population of adults with type 2 diabetes evaluating cardiovascular safety. The study showed that lixisenatide was non-inferior, although not superior, to placebo for cardiovascular safety. The results will be included in the U.S. New Drug Application of lixisenatide, which is on track to be resubmitted to the FDA in Q3. Lixisenatide is not approved in the U.S.
06:58 EDTSYNSynthetic Biologics announces positive PK results from SYN-004 trials
Subscribe for More Information
05:30 EDTSNYSanofi reports lixisenatide was non-inferior, though not superior to placebo
Subscribe for More Information
March 18, 2015
12:48 EDTBIIBFly Watch: Biogen predicted to report strong Alzheimer's data this Friday
Subscribe for More Information
09:32 EDTSNYMannKind faces cash shortfall if $100M debt not settled, TheStreet says
Subscribe for More Information
07:34 EDTBIIBBiogen should report strong Alzheimer's data, says RBC Capital
Subscribe for More Information
March 17, 2015
10:00 EDTISISOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Aimco (AIV) initiated with an Outperform at RW Baird... Alnylam (ALNY) initiated with a Buy at Janney Capital... American Campus (ACC) initiated with a Neutral at RW Baird... AvalonBay (AVB) initiated with a Neutral at RW Baird... BE Aerospace (BEAV) initiated with a Buy at CRT Capital... BlackRock (BLK) initiated with a Buy at Argus... Camden Property (CPT) initiated with an Outperform at RW Baird... CarMax (KMX) initiated with a Buy at Evercore ISI... Central Pacific (CPF) initiated with a Neutral at Macquarie... Cognex (CGNX) initiated with a Buy at Northcoast... Education Realty (EDR) initiated with a Neutral at RW Baird... EnerSys (ENS) initiated with an Overweight at Stephens... Equity Lifestyle (ELS) initiated with an Outperform at RW Baird... Equity Residential (EQR) initiated with a Neutral at RW Baird... Essex Property Trust (ESS) initiated with a Neutral at RW Baird... Facebook (FB) initiated with a Buy at Brean Capital... Intercept (ICPT) initiated with a Hold at MLV & Co.... Isis Pharmaceuticals (ISIS) initiated with a Neutral at Janney Capital... LinkedIn (LNKD) initiated with a Sell at Brean Capital... Mid-America Apartment (MAA) initiated with an Outperform at RW Baird... NetSuite (N) initiated with a Hold at Brean Capital... Paycom (PAYC) initiated with a Buy at Brean Capital... Platform Specialty Products (PAH) initiated with a Buy at UBS... Post Properties (PPS) initiated with a Neutral at RW Baird... Salesforce.com (CRM) initiated with a Hold at Brean Capital... ServiceNow (NOW) initiated with a Buy at Brean Capital... Snap-On (SNA) initiated with a Buy at Northcoast... Sun Communities (SUI) initiated with a Neutral at RW Baird... Twitter (TWTR) initiated with a Buy at Brean Capital... UDR, Inc. (UDR) initiated with an Outperform at RW Baird... Workday (WDAY) initiated with a Hold at Brean Capital... Xplore Technologies (XPLR) initiated with a Buy at Roth Capital... Yahoo (YHOO) initiated with a Hold at Argus.
10:00 EDTSNYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:20 EDTISISIsis Pharmaceuticals initiated with a Neutral at Janney Capital
Subscribe for More Information
08:02 EDTSNYSanofi says Shantha will provide up to 37M doses of Shan5
Sanofi Pasteur, the vaccines division of Sanofi, announced that its affiliate Shantha Biotechnics of Hyderabad, India has delivered the first 400,000 doses of its pediatric pentavalent vaccine Shan5 to support the immunization of children in the cities of Gwalior and Jabalpur, both in the state of Madhya Pradesh, India. In December 2014, following a two-year international tender, Shantha was awarded to supply global health organizations with a total of 37M doses of Shan5 in 2015 and 2016, in a ten-dose vial presentation. This tender provides the basis upon which purchase orders will be made for specific vaccine deliveries throughout the period, the company said.
07:43 EDTSNYSanofi upgraded to Outperform on abating concerns at Leerink
Leerink upgraded Sanofi to Outperform from Market Perform saying key concerns around the lack of a CEO, Toujeo positioning and guidance are either resolved or largely factored into expectations. The firm believes the company's currency risk is hedged over time and that its multibillion dollar PCSK9 and dupilumab therapy assumptions have further upside potential. It raised its price target for shares to EUR 106 from EUR 85.
05:40 EDTSNYSanofi upgraded to Outperform from Market Perform at Leerink
March 16, 2015
14:03 EDTSYNSynthetic Biologics downgraded to Hold from Buy at Maxim
Maxim downgraded Synthetic Biologics to Hold following management's decision no to move SYN-005 for pertussis until funding is found, which creates another uncertainty regarding the timeline. Price target is $3.
08:23 EDTSNYPCSK9 data continues to impress, says Leerink
Subscribe for More Information
07:16 EDTSNYRegeneron Sanofi dupilumab drug can generate $6B+ in revenue, says Bernstein
Bernstein believes that dupilumab, a drug made by Regeneron and Sanofi, has shown strong efficacy in patients with severe atopic dermatitis. The firm notes that the drug is currently in pivotal trials involving patients with severe levels of other common diseases. The firm thinks the drug can generate $1.5B of revenue by 2018 and $3.8B by 2020. Bernstein keeps a $500 price target and Outperform rating on Regeneron.
06:40 EDTSNYPCSK9 studies show potential improvement in heart health, WSJ says
Subscribe for More Information
March 15, 2015
13:04 EDTSNYSanofi, Regeneron announce publication of results of ODYSSEY long term trial
Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) today announced that 18-month results of a Phase 3 trial of Praluent, alirocumab, an investigational therapy, involving 2,341 high risk patients with hypercholesterolemia were published online in The New England Journal of Medicine. In the ODYSSEY LONG TERM trial, Praluent 150 mg every two weeks reduced low-density lipoprotein cholesterol by an additional 62% at week 24 when compared to placebo, the primary efficacy endpoint of the study, with consistent LDL-C lowering maintained over 78 weeks."These results demonstrated the durable efficacy for Praluent when added to maximally-tolerated statin therapy and further reinforce its generally consistent safety profile," said Jennifer Robinson, M.D., M.P.H., Director of the Prevention Intervention Center, Professor, Departments of Epidemiology & Medicine, College of Public Health at the University of Iowa. "Additionally, the post hoc analysis of major cardiovascular events represents an important finding for Praluent -- we look forward to results from the ongoing ODYSSEY OUTCOMES trial, which is prospectively evaluating the potential of Praluent to reduce cardiovascular events."
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use